{"id":250104,"date":"2025-12-01T00:00:00","date_gmt":"2025-12-01T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0060-biopharma-sjogrens-syndrome-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:24:08","modified_gmt":"2026-03-31T10:24:08","slug":"epidim0060-biopharma-sjogrens-syndrome-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0060-biopharma-sjogrens-syndrome-epidemiology-mature-markets\/","title":{"rendered":"Sjogren&#8217;s Syndrome &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of Sjogren\u2019s syndrome (<abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>, how many in each country across the major pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 16\u00a0<abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of associated <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed incident cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed incident cases of associated <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with lymphoma.<\/li>\n<li>Diagnosed prevalent cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> without lymphoma.<\/li>\n<li>Diagnosed prevalent cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with fibromyalgia.<\/li>\n<li>Diagnosed prevalent cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> without fibromyalgia.<\/li>\n<li>Diagnosed prevalent cases of associated <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with systemic lupus erythematosus (<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of associated <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of associated <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with systemic sclerosis.<\/li>\n<li>Diagnosed prevalent cases of secondary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with other autoimmune diseases.<\/li>\n<li>Diagnosed drug-treated prevalent cases of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed non-drug-treated prevalent cases of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250104","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-therapy-areas-sjogrens-syndrome","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250104\/revisions"}],"predecessor-version":[{"id":575273,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250104\/revisions\/575273"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}